MKMichel Abou Khalil

Michel Abou Khalil

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michel Abou Khalil has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pulmonary Vein Isolation Alone Versus Adjunctive Ablation for Paroxysmal Atrial Fibrillation

    by Michel Abou Khalil, Christian M. Massad, Eli Tsakiris, William Herbst, Maximilian Moersdorf, Mohammad Montaser Atasi, Yara Menassa, Alex El Darzi, Carlo El Khoury, Ghassan Bidaoui, et al.

    Background: Pulmonary vein isolation (PVI) is the standard ablation strategy for paroxysmal atrial fibrillation (PAF). Despite guideline recommendations favoring PVI alone in PAF, some operators routinely perform extra pulmonary vein ablation (PVI+) during initial procedures. Objective: To determine frequency of PVI+ strategy for treatment of PAF in the real world and examine its impact on arrhythmic recurrence and progression compared to PVI alone. Methods: Using the TriNetX research network, we identified adults with PAF who underwent catheter ablation between January 2020 and January 2024. Recurrence was defined as repeat ablation, cardioversion, or antiarrhythmic drug (AAD) use beyond a 3‐month blanking period. Progression to persistent AF and atypical atrial flutter were also assessed. Kaplan‐Meier analysis was performed with 3‐year follow‐up. Results: Before matching, 5134 of 18,891 patients (27.2%) underwent PVI+. In the propensity matched analysis ( n = 5020 per group), recurrence was significantly higher in the PVI+ group (HR 1.28, 95% CI 1.16–1.42; p < 0.001). Repeat ablation, cardioversion and AAD use were more common with PVI+ (HR 1.99, 95% CI 1.60–2.46; p < 0.0001, HR 1.37, 95% CI 1.13–1.66; p = 0.001, and HR 1.41, 95% CI 1.05–1.87; p = 0.020, respectively). Progression to persistent AF was higher with PVI+ (HR 1.37, 95% CI 1.23–1.53, p < 0.001), as was atypical atrial flutter (HR 2.63, 95% CI 1.97–3.50; p < 0.0001). Conclusion: Extra‐pulmonary vein ablation during first‐time PAF ablation remains common in real‐world practice but is associated with worse outcomes including repeat ablation, cardioversion, AAD use, atrial flutter, and progression to persistent AF.

  • Open Access

    Left Atrial Volume as Predictor of Recurrence After Pulmonary Vein Isolation

    by Mario Mekhael, Han Feng, Omar Kreidieh, Chao Huang, Eugene G. Kholmovski, Christian M. Massad, Michel Abou Khalil, Yara Menassa, Mohammad Montaser Atasi, Alex El Darzi, et al.

  • Open Access

    Repeat catheter ablation vs. direct current cardioversion for recurrent atrial fibrillation after prior ablation: a propensity-matched analysis

    by Michel Abou Khalil, Mohammad Montaser Atasi, Yara Menassa, Maximilian Moersdorf, Christian M Massad, Alex El Darzi, Carlo El Khoury, Yishi Jia, Ghassan Bidaoui, Hadi Younes, et al.

  • Open Access

    Female Sex Is Not a Uniform Risk Factor in Atrial Fibrillation

    by Cecile McGarvey, Emma Lunn, Yishi Jia, Yara Menassa, Yingshuo Liu, Mayana Bsoul, Christian Massad, Maximillian Moersdorf, Alex El Darazi, Michel Abou Khalil, et al.


  • Open Access

    Gastrointestinal Bleeding Risk Associated With Pulse Pressure in Patients With Atrial Fibrillation: A Retrospective Cohort Study (Preprint)

    by Michel Abou Khalil, Carlo El Khoury, Maximilian Moersdorf, Christian Massad, Alex El Darzi, Yara Menassa, Mohammad Montaser Atasi, Ghassan Bidaoui, Hadi Younes, Ala Assaf, et al.

    Background: Patients with atrial fibrillation (AF) face significant bleeding risks, particularly those receiving oral anticoagulation; however, existing risk scores such as HAS-BLED and ORBIT demonstrate limited predictive accuracy. Pulse pressure (PP), calculated as the difference between systolic blood pressure (SBP) and diastolic blood pressure, is a noninvasive marker of arterial stiffness that has been associated with cardiovascular outcomes. However, PP has not been evaluated as a predictor of bleeding in this population. Objective: This study evaluated whether elevated PP independently predicts major bleeding events, overall and by subtype, in patients with AF after adjusting for established clinical risk factors. Methods: We conducted a retrospective cohort study using electronic health records from REACHnet, a PCORnet-affiliated clinical data network in Louisiana. A total of 4935 adults (mean age 63.7, SD 11.0 y; n=1606, 32.5% female) with AF between 2010 and 2019 were included via consecutive sampling of all eligible patients. PP was derived from outpatient blood pressure measurements closest to AF diagnosis and analyzed in tertiles (low: 62 mm Hg) and continuously per 10 mm Hg. The primary outcome was time to the first bleeding event, a composite of gastrointestinal bleeding, intracranial hemorrhage, and other clinically significant bleeding, identified using ICD-9 / ICD-10 codes. Kaplan-Meier survival curves with log-rank testing were used for univariable analysis. Multivariable Cox proportional hazards regression was adjusted for age, sex, race, comorbidities, medications, and the ORBIT score. A sensitivity analysis applied multivariable logistic regression additionally incorporating SBP. Statistical significance was set at P <.05. Results: Over a 5-year follow-up, 677 out of 4935 (13.7%) patients experienced a bleeding event (intracranial hemorrhage: n=60, 1.2%; gastrointestinal bleeding: n=195, 4.0%; and other bleeding: n=149, 3.0%). Gastrointestinal bleeding differed significantly across PP tertiles ( P= .007). Kaplan-Meier analysis confirmed lower gastrointestinal bleeding-free survival in the highest tertile (log-rank P= .004). No significant differences were observed for intracranial ( P= .08), other ( P =.58), or composite bleeding ( P =.22). In multivariable Cox regression, each 1 mm Hg increase in PP was independently associated with a 1.4% higher gastrointestinal bleeding risk (hazard ratio 1.014, 95% CI 1.001‐1.028; P= .04), approximately 15% per 10 mm Hg. This remained significant after adjusting for SBP and ORBIT score (odds ratio 1.013/mm Hg, 95% CI 1.001‐1.025; P =.03), while SBP was not independently significant ( P =.13). Conclusions: PP independently predicts gastrointestinal bleeding risk in patients with AF beyond established clinical risk factors and validated bleeding risk scores. Unlike prior investigations that examined SBP or diastolic blood pressure components in isolation, this is the first study to identify PP as a predictor of gastrointestinal bleeding in this population. As a readily available, low-cost hemodynamic parameter derived from routine clinical measurements, PP could enhance existing risk stratification tools and inform more personalized bleeding risk management strategies in patients with AF.